Baxter International Inc. is a global healthcare company that develops, manufactures, and markets medical products, including intravenous solutions, renal therapies, and biosurgery products.
A fixed-income investment opportunity is presented by a bond issued by Baxter International Inc., a prominent global healthcare company renowned for its diverse portfolio of critical medical products, pharmaceuticals, and biotechnology solutions, serving patients worldwide with therapies for kidney disease, hemophilia, immune disorders, and other chronic and acute conditions. The United States-issued bond, identified by ISIN USU07181AY33 and CUSIP U07181AY3, is currently trading at 100% of its par value, denominated in USD. It carries a fixed annual coupon rate of 3.75%, with interest payments distributed semi-annually. The total issuance size for this debt instrument amounts to $750,000,000, with a minimum purchase threshold set at $2,000. This particular series of bonds is scheduled to mature on September 30, 2025, and has received a credit rating of A- from Standard & Poor's, reflecting its assessment of the issuer's creditworthiness.
|